Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells $28161.43 in Stock

Frederick Owens
September 14, 2017

Intercept Pharmaceuticals, given 6 buy equivalent recommendations, 0 sells and 3 holds. Liberum Capital downgraded the shares of ENQ in report on Tuesday, November 10 to "Sell" rating.

As close of Tuesday trade, Intercept Pharmaceuticals, Inc. BMO Capital Markets reaffirmed an "outperform" rating and set a $223.00 target price (up previously from $221.00) on shares of Intercept Pharmaceuticals in a research note on Friday, May 5th. Intercept Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $205.04.

LivePerson, maintained at an average outperform rating by 6 stock analysts, and there are at least 1.01% of shares outstanding that are now legally short sold. Currently EnLink Midstream, LLC (ENLC) has beta value of 2.59. Moreover, Deutsche Natl Bank Ag has 0.02% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 181,983 shares. The stock now has a Market Cap of $2.47B.

Company shares last traded at $97.30 significantly below the 50 day moving average of $112.57 and well below the 200 day moving average of $117.15. The stock carved out a 52-week low down at $96.63. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since September 13, 2016 and is downtrending.

As of the latest earnings report the EPS was $-15.49 and is estimated to be $-14.05 for the current year with 25,099,000 shares now outstanding. This estimate is provided by 15 analysts. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company's a year ago sales total was 5180.

More news: Target recalls furniture that may be harmful to children

"We do not anticipate this having any impact on our near-term market model assumptions since the population at risk represents only 3-5% of the overall PBC population and the treating clinician population is aware of risks with overdosing". Intercept Pharmaceuticals, Inc. (ICPT) is now moving with downbeat trend. (NASDAQ:ICPT) stock. It is widely believed that a stock's future performance can best be predicted by analyzing prior trends and patterns in price. If you are viewing this article on another domain, it was illegally copied and republished in violation of US and worldwide trademark and copyright law. Proshare Lc has invested 0.02% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). He kept his buy rating and 170 price target on Intercept. ICPT's SI was 5.06 million shares in September as released by FINRA. Everpoint Asset Mgmt Limited Company accumulated 9,200 shares or 0.02% of the stock. The stock was sold at an average price of $121.24, for a total transaction of $42,434.00. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in the company. Hudock Grp Lc stated it has 0% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Wedbush maintained the stock with "Outperform" rating in Wednesday, February 24 report. Germany-based Dekabank Deutsche Girozentrale has invested 0% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). The company is up 102.80 percent in the last four weeks, up 666.49 percent year-to-date, and up 413.59 percent during the past four quarters. In recent session, Intercept Pharmaceuticals, Inc. State Street Corp lifted its holdings in shares of Intercept Pharmaceuticals by 7.3% in the first quarter.

According to, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Ritu Baral has a yearly average return of 21.2% and a 54% success rate.

Intercept Pharmaceuticals, a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.

Other reports by LeisureTravelAid

Discuss This Article